Serina Therapeutics, INC 8-K filings

Serina Therapeutics appoints Dr. Jay Venkatesan to its Board of Directors and announces Dr. Milton Harris will transition to Director Emeritus and Chair of the Scientific Advisory Board.

Serina Therapeutics receives the second $5 million tranche of its $10 million equity financing to advance its SER-252 Parkinson's drug into a Phase 1 clinical trial.

Serina Therapeutics welcomes Karen J. Wilson to its Board of Directors and announces the departure of Steven Mintz.

Serina Therapeutics is developing a novel drug delivery platform, POZ, with a lead program targeting advanced Parkinson's disease and partnerships in RNA therapeutics and antibody-drug conjugates.

Serina Therapeutics divests its subsidiary, UniverXome Bioengineering, to Juvenescence in a deal involving debt assumption and a nominal cash payment.

Serina Therapeutics' stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve and implementing an automatic annual increase.

Serina Therapeutics announced its Chief Development Officer presented data at the 3rd Annual LNP Immunogenicity & Toxicity Summit, highlighting the potential of its POZ-lipid technology to improve the safety of mRNA-based vaccines.

Serina Therapeutics has secured a $10 million investment from JuvVentures to fund the advancement of its lead drug candidate for Parkinson's disease into Phase 1 clinical trials.

Serina Therapeutics announced its third quarter 2024 financial results, highlighting a partnership with Enable Injections and progress on its lead candidate SER-252.

Serina Therapeutics' Chief Development Officer will present at the 14th Annual Injectables Summit, highlighting their partnership with Enable Injections for advanced Parkinson's disease treatment.

Serina Therapeutics has appointed Steven Ledger, previously interim CEO, as its permanent Chief Executive Officer, effective September 8, 2024.

Serina Therapeutics' Interim CEO, Steve Ledger, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024.

Serina Therapeutics has appointed Gregory S. Curhan as its new Chief Financial Officer, effective August 16, 2024, while also announcing the departure of interim CFO Andrea Park.

Serina Therapeutics reported its second quarter 2024 financial results, highlighted by a new partnership and advancements in its POZ platform technology.

Serina Therapeutics announced its Chief Development Officer will present novel data on its POZ-lipid technology at the 4th Annual mRNA-Based Therapeutics Summit, highlighting its potential to enhance the safety and efficacy of mRNA-LNP formulations.

Serina Therapeutics has appointed Dr. Srini Tenjarla as Senior Vice President of CMC and Formulation, bringing over 20 years of drug development experience to the company.

Serina Therapeutics' Chief Operating Officer, Tacey Viegas, will retire on July 15, 2024, and transition to a consulting role with the company.

Serina Therapeutics received approximately $4.99 million from Juvenescence Limited through the exercise of warrants, with plans to use the funds for general corporate purposes.

Serina Therapeutics announced its first quarter 2024 financial results, highlighting the advancement of its lead drug candidate and the completion of its merger with AgeX Therapeutics.

Serina Therapeutics has replaced its auditor, WithumSmith+Brown, with Frazier & Deeter following the completion of its merger with AgeX Therapeutics.

Serina Therapeutics has appointed Dr. Simba Gill as Executive Chairman, effective April 12, 2024, to guide the company's strategic growth and development.

Serina Therapeutics has finalized its merger with AgeX Therapeutics, commencing trading under the ticker symbol SER and prioritizing the advancement of its lead drug candidate.

AgeX Therapeutics reported a net loss of $14.8 million for 2023, with operating expenses increasing significantly compared to the previous year.

AgeX Therapeutics has completed a 1-for-35.17 reverse stock split and secured stockholder approval for key merger proposals with Serina Therapeutics.

AgeX Therapeutics has drawn $500,000 from its credit facility, declared a warrant dividend, and plans a reverse stock split, all in connection with its merger with Serina Therapeutics.

AgeX Therapeutics has extended its loan repayment date with Juvenescence to May 9, 2024, and drawn an additional $500,000 from its credit facility.

AgeX Therapeutics drew $500,000 from its existing credit facility and experienced a potential change of control as Juvenescence increased its stake to 75.6% following a conversion of preferred stock to common stock.

AgeX Therapeutics has drawn $500,000 from its credit facility with Juvenescence Limited, with repayment due on February 14, 2024.

AgeX Therapeutics has appointed Steven Mintz to its Board of Directors, increasing the board size to four members, and he will serve on multiple committees.